Clinical trials: Glabellar Lines
Hyperhidrosis, Muscle Spasticity
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal…
- Conditions
- Hyperhidrosis, Muscle Spasticity, Glabellar Lines
- Trial name
- NCT02043145
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 727 people
- Sponsor
- Allergan
Upper Facial Rhytides, Crow's Feet Lines
BOTOX® in the Treatment of Upper Facial Lines in Japan
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) for the treatment of upper facial lines (Crow's Feet Lines and Frown Lines).
- Conditions
- Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Frown Lines
- Trial name
- NCT01797094
- Testing
- botulinum toxin Type A (44U), botulinum toxin Type A (32U)
- Where
- Japan
- Volunteers
- 101 people
- Sponsor
- Allergan
Facial Rhytides, Crow's Feet Lines
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
A study to evaluate patient satisfaction, aesthetic and psychological impact of combined treatment with BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE®…
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
- Trial name
- NCT02176356
- Testing
- onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Allergan
Glabellar Lines, Lateral Canthal Lines
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
To evaluate the long-term safety of MT10109L in the treatment of GL and/or LCL in participants with moderate to severe GL and/or LCL.
- Trial name
- NCT04157686
- Testing
- MT10109L Dose 1, MT10109L Dose 2, MT10109L Dose 1 + Dose 2
- Where
- 38 sites in United States, Belgium and 4 more
- Volunteers
- 957 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Xeomin for a total of 16 weeks after the administration in treatment of glabellar frown lines.
- Trial name
- NCT05623410
- Testing
- ATGC-110, Xeomin®
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- ATGC Co., Ltd.
Glabellar Frown Lines
Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to BOTOX in treatment of glabellar lines.
- Trial name
- NCT05059587
- Testing
- MBA-P01, BOTOX
- Where
- South Korea
- Volunteers
- 318 people
- Sponsor
- Medytox Korea
Glabellar Frown Lines
The Treatment of Glabellar Frown Lines
The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).
- Trial name
- NCT02096081
- Testing
- IncobotulinumtoxinA, OnabotulinumtoxinA
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Merz North America, Inc.
Glabellar Lines, Lateral Canthal Lines
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.
- Trial name
- NCT03721016
- Testing
- MT10109L
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 415 people
- Sponsor
- Medy-Tox
Glabellar Lines
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
The objective of this study is to demonstrate the efficacy of Dysport for the improvement in appearance of moderate to severe glabellar lines and to assess the short term and long term safety of Dysport, used for the improvement…
- Trial name
- NCT02450526
- Testing
- Botulinum toxin type A
- Where
- 10 sites in China
- Volunteers
- 520 people
- Sponsor
- Ipsen
Glabellar Lines
Study of DWP450 in Japanese Subjects With Glabellar Lines
Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects with Moderate to Severe Glabellar Lines
- Trial name
- NCT07783763
- Testing
- DWP450 20 U, 0.9% Saline Solution 0.5 mL
- Volunteers
- 120 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Lines
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
A Randomized, Double-blind, Active-controlled, Multi-center Phase 3 Trial to Investigate the Efficacy and Safety of CKDB-501A in Subjects with Moderated-to-severe Glabella Lines
- Trial name
- NCT05804656
- Testing
- CKDB-501A, Botox®
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- CKD Bio Corporation
Glabellar Frown Lines (GL)
Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar frown lines (GL).
- Trial name
- NCT02939326
- Testing
- EB-001 injection
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Bonti, Inc.
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA II (NCT04622254)
- Testing
- NT 201
- Where
- 12 sites in Germany
- Volunteers
- 368 people
- Sponsor
- Merz North America, Inc.
Glabellar Frown Lines
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.
- Trial name
- NCT04830345
- Testing
- ATGC-100 100U, Botox 100U
- Where
- South Korea
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Moderate to Severe Glabellar Lines
Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT06151561
- Testing
- AGN-151586
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- AbbVie
Glabellar Frown Lines
Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL).
- Trial name
- NCT06411002
- Testing
- DAXXIFY
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines
To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.
To compare the safety and efficacy of "HG-102" with Botox® in the improvement of moderate to severe glabellar lines.
- Trial name
- NCT04944953
- Testing
- Botulinum Toxin Type A Injection [Botox], Botulinum toxin type A injection [HG-102]
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Hugel
Glabellar Lines
A Study to Evaluate AI-09 In Participants With Glabellar Lines
Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.
- Trial name
- NCT07321834
- Testing
- AI-09 Ready Use Injectable Botulinum Toxin, Vehicle
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- Eirion Therapeutics Inc.
Glabellar Lines
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.
- Trial name
- NCT06212960
- Testing
- DWP712, BOTOX®
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Frown Lines
Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line
This study design is a parallel, active drug controlled, double blind, randomized, multi-centered, phase III clinical trial to compare the efficacy and safety of MT10107 versus BOTOX® in treatment of glabella line.
- Trial name
- NCT03908008
- Testing
- Botox (Botulinum toxin type A), MT10107 (Botulinum toxin type A)
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Medy-Tox